SAB Biotherapeutics (SABS) Enterprise Value (2020 - 2026)
SAB Biotherapeutics' (SABS) quarterly Enterprise Value came in at -$107.4 million in Q1 2026, down 735.71% YoY from $16.9 million in Q1 2025, and down 11.18% on a QoQ basis from -$96.6 million in Q4 2025.
SAB Biotherapeutics (SABS) Enterprise Value (2020 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 7 years of Enterprise Value data on file, last reported at -$107.4 million in Q1 2026.
- Quarterly Enterprise Value fell 735.71% year-over-year to -$107.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$107.4 million (down 735.71% YoY) and the FY2025 annual result came in at -$96.6 million, down 365.27% from the prior year.
- Enterprise Value declined to -$107.4 million in Q1 2026, from -$96.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$2.4 million in Q3 2023 to a low of -$110.9 million in Q3 2025.
- A 5-year average of -$35.8 million and a median of -$20.8 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value slumped 1153.39% — and 2025, when it jumped 84.68%.
- Tracing SABS's Enterprise Value over 5 years: stood at -$15.0 million in 2022, then plunged by 275.93% to -$56.6 million in 2023, then surged by 63.3% to -$20.8 million in 2024, then sank by 365.27% to -$96.6 million in 2025, then fell by 11.18% to -$107.4 million in 2026.
- The last three Enterprise Value figures came in at -$107.4 million (Q1 2026), -$96.6 million (Q4 2025), and -$110.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - | -102.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -102.63 Mn |
| Mar 31, 2026 | -107.39 Mn |
| Dec 31, 2025 | -96.59 Mn |
| Sep 30, 2025 | -110.88 Mn |
| Jun 30, 2025 | -5.71 Mn |
| Mar 31, 2025 | -12.85 Mn |
| Dec 31, 2024 | -20.76 Mn |
| Sep 30, 2024 | -30.40 Mn |
| Jun 30, 2024 | -37.28 Mn |
| Mar 31, 2024 | -44.06 Mn |
| Dec 31, 2023 | -56.57 Mn |
| Sep 30, 2023 | -2.43 Mn |
| Jun 30, 2023 | -7.77 Mn |
| Mar 31, 2023 | -13.06 Mn |
| Dec 31, 2022 | -15.05 Mn |
| Sep 30, 2022 | -8.33 Mn |
| Jun 30, 2022 | -16.62 Mn |
| Mar 31, 2022 | -22.41 Mn |
| Dec 31, 2021 | -39.55 Mn |
| Sep 30, 2021 | -10.75 Mn |